We serve Chemical Name:Lynestrenol CAS:52-76-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Lynestrenol
CAS.NO:52-76-6
Synonyms:exluten;exlution;org485-50;19-Nor-4-pregnen-20-yn-17β-ol;LYNDIOL;MFCD00051135;orgametil;EINECS 200-151-4;19-Norpregn-4-en-20-yn-17-ol;(17α)-17-ethynylestr-4-en-17-ol;ethinylestrenol;Exlutena;lynoestrenol;exluton;Estr-4-en-17-ol, 17-ethynyl-, (17α)-;Lynestrenol;lynenol;exlutona
Molecular Formula:C20H28O
Molecular Weight:284.436
HS Code:
Physical and Chemical Properties:
Melting point:158ºC
Boiling point:399.6±42.0 °C at 760 mmHg
Density:1.1±0.1 g/cm3
Index of Refraction:1.568
PSA:20.23000
Exact Mass:284.214020
LogP:5.83
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like exluten chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,exlutona physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Estr-4-en-17-ol, 17-ethynyl-, (17α)- Use and application,(17α)-17-ethynylestr-4-en-17-ol technical grade,usp/ep/jp grade.
Related News: The API can be directly formulated, and the intermediate can only be used to synthesize the next product. Only through the intermediate can the API be manufactured. Lynestrenol manufacturer In its message to the public, the FDA said that a person should consider being retested if they used Innova’s diagnostic within the past two weeks. Lynestrenol supplier The API can be directly formulated, and the intermediate can only be used to synthesize the next product. Only through the intermediate can the API be manufactured. Lynestrenol vendor The target screening performed by Retrogenix will focus on hundreds of novel, prioritized antibodies in Resonant��s collection. Lynestrenol factory The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG��s pharmaceutical business within the Corden Pharma platform. The companies�� goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed.
